Teacher Retirement System of Texas Cuts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Teacher Retirement System of Texas lessened its position in Illumina, Inc. (NASDAQ:ILMN) by 10.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 582,478 shares of the life sciences company’s stock after selling 66,550 shares during the quarter. Teacher Retirement System of Texas’ holdings in Illumina were worth $77,837,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ILMN. Bleakley Financial Group LLC purchased a new position in Illumina in the 4th quarter valued at $751,000. Zacks Investment Management acquired a new stake in shares of Illumina during the third quarter valued at about $2,924,000. Van ECK Associates Corp lifted its stake in Illumina by 17.5% during the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after purchasing an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC purchased a new position in Illumina during the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP increased its stake in Illumina by 720.7% during the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock worth $1,001,000 after purchasing an additional 6,263 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Royal Bank of Canada dropped their price objective on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday, March 12th. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Citigroup reduced their price objective on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Barclays reissued an “underweight” rating on shares of Illumina in a research note on Tuesday, March 11th. Finally, Morgan Stanley reduced their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $140.90.

Illumina Stock Performance

Shares of ILMN stock opened at $84.96 on Thursday. The stock’s 50-day moving average is $110.28 and its two-hundred day moving average is $128.89. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The firm has a market cap of $13.46 billion, a price-to-earnings ratio of -11.06, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.